<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE root>
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="other" dtd-version="1.2" xml:lang="en"><front><journal-meta><journal-id journal-id-type="publisher-id">Advances in Molecular Oncology</journal-id><journal-title-group><journal-title xml:lang="en">Advances in Molecular Oncology</journal-title><trans-title-group xml:lang="ru"><trans-title>Успехи молекулярной онкологии</trans-title></trans-title-group></journal-title-group><issn publication-format="print">2313-805X</issn><issn publication-format="electronic">2413-3787</issn><publisher><publisher-name xml:lang="en">Publishing House ABV Press</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">417</article-id><article-id pub-id-type="doi">10.17650/2313-805X-2022-9-1-57-63</article-id><article-categories><subj-group subj-group-type="toc-heading" xml:lang="en"><subject>RESEARCH ARTICLES</subject></subj-group><subj-group subj-group-type="toc-heading" xml:lang="ru"><subject>ЭКСПЕРИМЕНТАЛЬНЫЕ СТАТЬИ</subject></subj-group><subj-group subj-group-type="article-type"><subject></subject></subj-group></article-categories><title-group><article-title xml:lang="en">Comprehensive analysis of chromosome 8 abnormalities and its prognostic value in patients with uveal melanoma</article-title><trans-title-group xml:lang="ru"><trans-title>Комплексный анализ прогностической значимости аберраций хромосомы 8 у пациентов с увеальной меланомой</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0001-8937-7450</contrib-id><name-alternatives><name xml:lang="en"><surname>Yarovaya</surname><given-names>V. A.</given-names></name><name xml:lang="ru"><surname>Яровая</surname><given-names>В. А.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p><bold>Vera Andreevna Yarovaya</bold> </p><p>59 Beskudnikovsky Bul’var, Moscow127486</p></bio><bio xml:lang="ru"><p><bold>Вера Андреевна Яровая</bold>  </p><p>127486 Москва, Бескудниковский бульвар, 59</p></bio><email>verandreevna@gmail.com</email><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0003-2219-7054</contrib-id><name-alternatives><name xml:lang="en"><surname>Yarovoy</surname><given-names>A. A.</given-names></name><name xml:lang="ru"><surname>Яровой</surname><given-names>А. А.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>59 Beskudnikovsky Bul’var, Moscow127486</p></bio><bio xml:lang="ru"><p>127486 Москва, Бескудниковский бульвар, 59</p></bio><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-8592-1188</contrib-id><name-alternatives><name xml:lang="en"><surname>Chudakova</surname><given-names>L. V.</given-names></name><name xml:lang="ru"><surname>Чудакова</surname><given-names>Л. В.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>1 Ostrovityanova St., Moscow 117997</p></bio><bio xml:lang="ru"><p>117997 Москва, улица Островитянова, 1</p></bio><xref ref-type="aff" rid="aff2"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0001-6949-1002</contrib-id><name-alternatives><name xml:lang="en"><surname>Levashov</surname><given-names>I. A.</given-names></name><name xml:lang="ru"><surname>Левашов</surname><given-names>И. А.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>59 Beskudnikovsky Bul’var, Moscow127486</p></bio><bio xml:lang="ru"><p>127486 Москва, Бескудниковский бульвар, 59</p></bio><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-7778-6617</contrib-id><name-alternatives><name xml:lang="en"><surname>Zaretskiy</surname><given-names>A. R.</given-names></name><name xml:lang="ru"><surname>Зарецкий</surname><given-names>А. Р.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>1 Ostrovityanova St., Moscow 117997</p></bio><bio xml:lang="ru"><p>117997 Москва, улица Островитянова, 1</p></bio><xref ref-type="aff" rid="aff2"/></contrib></contrib-group><aff-alternatives id="aff1"><aff><institution xml:lang="en">S.N. Fedorov MNTC «Eye Microsurgery», Ministry of Health of Russia</institution></aff><aff><institution xml:lang="ru">ФГАУ НМИЦ «МНТК «Микрохирургия глаза» им. акад. С.Н. Федорова» Минздрава России</institution></aff></aff-alternatives><aff-alternatives id="aff2"><aff><institution xml:lang="en">N.I. Pirogov Russian National Research Medical University, Ministry of Health of Russia</institution></aff><aff><institution xml:lang="ru">ФГАОУ ВО «Российский национальный исследовательский медицинский университет им. Н.И. Пирогова» Минздрава России</institution></aff></aff-alternatives><pub-date date-type="pub" iso-8601-date="2022-01-15" publication-format="electronic"><day>15</day><month>01</month><year>2022</year></pub-date><volume>9</volume><issue>1</issue><issue-title xml:lang="en"/><issue-title xml:lang="ru"/><fpage>57</fpage><lpage>63</lpage><history><date date-type="received" iso-8601-date="2022-03-18"><day>18</day><month>03</month><year>2022</year></date><date date-type="accepted" iso-8601-date="2022-03-18"><day>18</day><month>03</month><year>2022</year></date></history><permissions><copyright-statement xml:lang="en">Copyright ©; 2022, Yarovaya V.A., Yarovoy A.A., Chudakova L.V., Levashov I.A., Zaretskiy A.R.</copyright-statement><copyright-statement xml:lang="ru">Copyright ©; 2022, Яровая В.А., Яровой А.А., Чудакова Л.В., Левашов И.А., Зарецкий А.Р.</copyright-statement><copyright-year>2022</copyright-year><copyright-holder xml:lang="en">Yarovaya V.A., Yarovoy A.A., Chudakova L.V., Levashov I.A., Zaretskiy A.R.</copyright-holder><copyright-holder xml:lang="ru">Яровая В.А., Яровой А.А., Чудакова Л.В., Левашов И.А., Зарецкий А.Р.</copyright-holder><ali:free_to_read xmlns:ali="http://www.niso.org/schemas/ali/1.0/"/><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/">https://creativecommons.org/licenses/by/4.0</ali:license_ref></license></permissions><self-uri xlink:href="https://umo.abvpress.ru/jour/article/view/417">https://umo.abvpress.ru/jour/article/view/417</self-uri><abstract xml:lang="en"><p><bold>Introduction.</bold> Uveal melanoma ability to metastasize depends on a few prognostic factors. The genetic ones are considered to be the most significant. The role of disorders of the short arm of chromosome 8 (8p), as well as a combination of changes in 8p and the long arm of this chromosome (8q) in the development of metastatic lesions in this pathology remains insufficiently studied.<bold>The study objective</bold> – to evaluate the prognostic value of chromosome 8 abnormalities in patients with uveal melanoma.<bold>Materials and methods.</bold> We analyzed 2 retrospective groups of patients who underwent enucleation for uveal melanoma, statistically homogeneous in the main clinical parameters. Group 1 included patients without signs of metastases (n = 41) with an average follow-up period of 71 months, Group 2 included patients with detected metastases (n = 51) and an average follow-up period of 21 months Chromosome abnormalities were tested by multiplex ligation-dependent probe amplification.<bold>Results.</bold> Three- and five-year survival in patients with uveal melanoma without 8p deletion were 64 and 54 %, respectively; with 8p deletion significantly lower – 25 and 6 %, respectively. The same survival rates in patients with uveal melanoma with 8q amplification were 43 and 26 %, respectively, whereas in patients without 8q amplification they were significantly higher – 80 and 74 %, respectively. In patients with uveal melanoma harbouring both abnormalities, 3- and 5-year survival rates were 26 and 7 %, whereas isolated 8q amplification was associated with 47 and 35 % survival, respectively. These survival rates differ greatly and significantly: hazard ratio 3,26 (95 % confidence interval 1,86–5,69) and 6,89 (95 % confidence interval 2,67–17,73), respectively (р &lt;0,0001).<bold>Conclusion.</bold> The findings support comprehensive evaluation of chromosome 8 abnormalities as a substantial part of uveal melanoma prognostication. 8q amplification, 8p deletion, combination of these abnormalities and its role in uveal melanoma malignity should be further discovered. Further research in this direction is needed.</p></abstract><trans-abstract xml:lang="ru"><p><bold>Введение.</bold> Способность увеальной меланомы к метастазированию зависит от целого спектра прогностических факторов, среди которых генетические имеют основополагающее значение. Роль нарушений короткого плеча хромосомы 8 (8р), а также комбинации изменений 8р и длинного плеча этой хромосомы (8q) в развитии метастатического поражения при данной патологии остается недостаточно изученной.<bold>Цель исследования</bold> – проведение комплексного анализа прогностической значимости аберраций хромосомы 8 у пациентов с увеальной меланомой.<bold>Материалы и методы.</bold> Были проанализированы 2 ретроспективные группы пациентов, которым была проведена энуклеация по поводу увеальной меланомы, статистически однородные по основным клиническим параметрам. В 1-ю группу вошли больные без признаков метастазов (n = 41) со средним сроком наблюдения 71 мес, во 2-ю группу – больные с выявленными метастазами (n = 51) и средним сроком наблюдения 21 мес. анализ хромосомных нарушений проводился методом мультиплексной амплификации лигированных зондов.<bold>Результаты.</bold> Трех- и 5-летняя выживаемость пациентов с увеальной меланомой без делеции 8p составила 64 и 54 %, с делецией 8p – 25 и 6 % соответственно. У больных с амплификацией 8q эти показатели были равны 43 и 26 %, у больных без амплификации 8q – 80 и 74 % соответственно. Для пациентов с одновременной амплификацией региона 8q и делецией региона 8р 3- и 5-летняя выживаемость составила 26 и 7 %, тогда как для пациентов с изолированной амплификацией 8q – 47 и 35 % соответственно. Уровень выживаемости пациентов с изолированной амплификацией 8q и комбинацией нарушений (del8p + amp8q) различается существенно и достоверно: отношение рисков 3,26 (95 % доверительный интервал 1,86–5,69) и 6,89 (95 % доверительный интервал 2,67–17,73) (р &lt;0,0001).<bold>Заключение.</bold> Оценка амплификации 8q, делеции 8p и комбинации этих нарушений должна стать неотъемлемой частью прогнозирования риска метастазирования увеальной меланомы. Необходимы дальнейшие исследования в этом направлении.</p></trans-abstract><kwd-group xml:lang="en"><kwd>ocular oncology</kwd><kwd>molecular oncology</kwd><kwd>uveal melanoma</kwd><kwd>prognostication</kwd><kwd>survival rate</kwd></kwd-group><kwd-group xml:lang="ru"><kwd>офтальмоонкология</kwd><kwd>молекулярная онкология</kwd><kwd>увеальная меланома</kwd><kwd>прогнозирование</kwd><kwd>выживаемость</kwd></kwd-group><funding-group><funding-statement xml:lang="en">The study was conducted with the support of the Ministry of Health of Russia (state task 300060056 for the Federal State Educational Institution of theN.I. Pirogov Russian National Research Medical University, Ministry of Health of Russia).</funding-statement><funding-statement xml:lang="ru">Исследование проведено при поддержке Министерства здравоохранения Российской Федерации (государственное задание 300060056 для ФГАОУ ВО «Российский национальный исследовательский медицинский университет им. Н.И. Пирогова» Минздрава России).</funding-statement></funding-group></article-meta></front><body></body><back><ref-list><ref id="B1"><label>1.</label><citation-alternatives><mixed-citation xml:lang="en">1. Onken M.D., Worley L.A., Char D.H. et al. Collaborative Ocular Oncology Group Report Number 1: prospective validation of a multi-gene prognostic assay in uveal melanoma. Ophthalmology 2012;119(8):1596–603. DOI: 10.1016/j.ophtha.2012.02.017.</mixed-citation><mixed-citation xml:lang="ru">Onken M.D., Worley L.A., Char D.H. et al. Collaborative Ocular Oncology Group Report Number 1: prospective validation of a multi-gene prognostic assay in uveal melanoma. Ophthalmology 2012;119(8):1596–603. DOI: 10.1016/j.ophtha.2012.02.017.</mixed-citation></citation-alternatives></ref><ref id="B2"><label>2.</label><citation-alternatives><mixed-citation xml:lang="en">2. Singh A.D., Zabor E.C., Radivoyevitch T. Estimating cured fractions of uveal melanoma. JAMA Ophthalmol 2021;139(2):174– 81. DOI: 10.1001/jamaophthalmol.2020.5720.</mixed-citation><mixed-citation xml:lang="ru">Singh A.D., Zabor E.C., Radivoyevitch T. Estimating cured fractions of uveal melanoma. JAMA Ophthalmol 2021;139(2):174– 81. DOI: 10.1001/jamaophthalmol.2020.5720.</mixed-citation></citation-alternatives></ref><ref id="B3"><label>3.</label><citation-alternatives><mixed-citation xml:lang="en">3. Jager M.J., Shields C.L., Cebulla C.M. et al. Uveal melanoma. Nat Rev Dis Primers 2020;6(1):24. DOI: 10.1038/s41572-020-0158-0.</mixed-citation><mixed-citation xml:lang="ru">Jager M.J., Shields C.L., Cebulla C.M. et al. Uveal melanoma. Nat Rev Dis Primers 2020;6(1):24. DOI: 10.1038/s41572-020-0158-0.</mixed-citation></citation-alternatives></ref><ref id="B4"><label>4.</label><citation-alternatives><mixed-citation xml:lang="en">4. Mazloumi M., Vichitvejpaisal P., Dalvin L.A. et al. Accuracy of The Cancer Genome Atlas Classification vs american joint committee on cancer classification for prediction of metastasis in patients with uveal melanoma. JAMA Ophthalmol 2020;138(3):260–7. DOI: 10.1001/jamaophthalmol.2019.5710.</mixed-citation><mixed-citation xml:lang="ru">Mazloumi M., Vichitvejpaisal P., Dalvin L.A. et al. Accuracy of The Cancer Genome Atlas Classification vs american joint committee on cancer classification for prediction of metastasis in patients with uveal melanoma. JAMA Ophthalmol 2020;138(3):260–7. DOI: 10.1001/jamaophthalmol.2019.5710.</mixed-citation></citation-alternatives></ref><ref id="B5"><label>5.</label><citation-alternatives><mixed-citation xml:lang="en">5. Jager M.J., Brouwer N.J., Esmaeli B. The Cancer Genome Atlas Project: an integrated molecular view of uveal melanoma. Ophthalmology 2018;125(8):1139–42. DOI: 10.1016/j.ophtha.2018.03.011.</mixed-citation><mixed-citation xml:lang="ru">Jager M.J., Brouwer N.J., Esmaeli B. The Cancer Genome Atlas Project: an integrated molecular view of uveal melanoma. Ophthalmology 2018;125(8):1139–42. DOI: 10.1016/j.ophtha.2018.03.011.</mixed-citation></citation-alternatives></ref><ref id="B6"><label>6.</label><citation-alternatives><mixed-citation xml:lang="en">6. Dogrusöz M., Jager M.J. Genetic prognostication in uveal melanoma. Acta Ophthalmol 2018;96(4):331–47. DOI: 10.1111/aos.13580.</mixed-citation><mixed-citation xml:lang="ru">Dogrusöz M., Jager M.J. Genetic prognostication in uveal melanoma. Acta Ophthalmol 2018;96(4):331–47. DOI: 10.1111/aos.13580.</mixed-citation></citation-alternatives></ref><ref id="B7"><label>7.</label><citation-alternatives><mixed-citation xml:lang="en">7. Royer-Bertrand B., Torsello M., Rimoldi D. et al. Comprehensive genetic landscape of uveal melanoma by whole genome sequencing. Am J Hum Genet 2016;99(5):1190–8. DOI: 10.1016/j.ajhg.2016.09.008.</mixed-citation><mixed-citation xml:lang="ru">Royer-Bertrand B., Torsello M., Rimoldi D. et al. Comprehensive genetic landscape of uveal melanoma by whole genome sequencing. Am J Hum Genet 2016;99(5):1190–8. DOI: 10.1016/j.ajhg.2016.09.008.</mixed-citation></citation-alternatives></ref><ref id="B8"><label>8.</label><citation-alternatives><mixed-citation xml:lang="en">8. Shields C.L., Ganguly A., Bianciotto C.G. et al. Prognosis of uveal melanoma in 500 cases using genetic testing of fineneedle aspiration biopsy specimens. Ophthalmology 2011;118(2):396–401. DOI: 10.1016/j.ophtha.2010.05.023.</mixed-citation><mixed-citation xml:lang="ru">Shields C.L., Ganguly A., Bianciotto C.G. et al. Prognosis of uveal melanoma in 500 cases using genetic testing of fineneedle aspiration biopsy specimens. Ophthalmology 2011;118(2):396–401. DOI: 10.1016/j.ophtha.2010.05.023.</mixed-citation></citation-alternatives></ref><ref id="B9"><label>9.</label><citation-alternatives><mixed-citation xml:lang="en">9. Robertson A.G., Shih J., Yau C. et al. Integrative analysis identifies four molecular and clinical subsets in uveal melanoma. Cancer Cell 2017;32(2):204– 20.e15. DOI: 10.1016/j.ccell.2017.07.003.</mixed-citation><mixed-citation xml:lang="ru">Robertson A.G., Shih J., Yau C. et al. Integrative analysis identifies four molecular and clinical subsets in uveal melanoma. Cancer Cell 2017;32(2):204– 20.e15. DOI: 10.1016/j.ccell.2017.07.003.</mixed-citation></citation-alternatives></ref><ref id="B10"><label>10.</label><citation-alternatives><mixed-citation xml:lang="en">10. Damato B., Duke C., Coupland S.E. et al. Cytogenetics of uveal melanoma. Ophthalmology 2007;114(10):1925–31. DOI: 10.1016/j.ophtha.2007.06.012.</mixed-citation><mixed-citation xml:lang="ru">Damato B., Duke C., Coupland S.E. et al. Cytogenetics of uveal melanoma. Ophthalmology 2007;114(10):1925–31. DOI: 10.1016/j.ophtha.2007.06.012.</mixed-citation></citation-alternatives></ref><ref id="B11"><label>11.</label><citation-alternatives><mixed-citation xml:lang="en">11. Shields C.L., Say E.A.T., Hasanreisoglu M. et al. Cytogenetic abnormalities in uveal melanoma based on tumor features and size in 1059 patients. Ophthalmology 2017;124(5):609–18. DOI: 10.1016/j.ophtha.2016.12.026.</mixed-citation><mixed-citation xml:lang="ru">Shields C.L., Say E.A.T., Hasanreisoglu M. et al. Cytogenetic abnormalities in uveal melanoma based on tumor features and size in 1059 patients. Ophthalmology 2017;124(5):609–18. DOI: 10.1016/j.ophtha.2016.12.026.</mixed-citation></citation-alternatives></ref><ref id="B12"><label>12.</label><citation-alternatives><mixed-citation xml:lang="en">12. Vichitvejpaisal P., Dalvin L.A., Mazloumi M. et al. Genetic analysis of uveal melanoma in 658 patients using the cancer genome atlas classification of uveal melanoma as A, B, C, and D. Ophthalmology 2019;126(10):1445–53. DOI: 10.1016/j.ophtha.2019.04.027.</mixed-citation><mixed-citation xml:lang="ru">Vichitvejpaisal P., Dalvin L.A., Mazloumi M. et al. Genetic analysis of uveal melanoma in 658 patients using the cancer genome atlas classification of uveal melanoma as A, B, C, and D. Ophthalmology 2019;126(10):1445–53. DOI: 10.1016/j.ophtha.2019.04.027.</mixed-citation></citation-alternatives></ref><ref id="B13"><label>13.</label><citation-alternatives><mixed-citation xml:lang="en">13. Shields C.L., Say E.A.T., Hasanreisoglu M. et al. Personalized prognosis of uveal melanoma based on cytogenetic profile in 1059 patients over an 8-year period. Ophthalmology 2017;124(10):1523–31. DOI: 10.1016/j.ophtha.2017.04.003.</mixed-citation><mixed-citation xml:lang="ru">Shields C.L., Say E.A.T., Hasanreisoglu M. et al. Personalized prognosis of uveal melanoma based on cytogenetic profile in 1059 patients over an 8-year period. Ophthalmology 2017;124(10):1523–31. DOI: 10.1016/j.ophtha.2017.04.003.</mixed-citation></citation-alternatives></ref><ref id="B14"><label>14.</label><citation-alternatives><mixed-citation xml:lang="en">14. Ewens K.G., Kanetsky P.A., RichardsYutz J. et al. Genomic profile of 320 uveal melanoma cases: chromosome 8p-loss and metastatic outcome. Investigative Opthalmology &amp; Visual Science 2013;54(8):5721–9. DOI: 10.1167/iovs.13-12195.</mixed-citation><mixed-citation xml:lang="ru">Ewens K.G., Kanetsky P.A., RichardsYutz J. et al. Genomic profile of 320 uveal melanoma cases: chromosome 8p-loss and metastatic outcome. Investigative Opthalmology &amp; Visual Science 2013;54(8):5721–9. DOI: 10.1167/iovs.13-12195.</mixed-citation></citation-alternatives></ref></ref-list></back></article>
